Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer

Anticancer Research

Volumn 25, Issue 2 B, 2005, Pages 1309-1314

  Vici, Patrizia ^a   Foggi, Paolo ^a   Colucci, Giuseppe ^b   Capomolla, Elisabetta ^a   Brandi, Mario ^b   Giotta, Francesco ^b   Gebbia, Nicola ^c   Di Lauro, Luigi ^a   Valerio, Maria Rosaria ^c   Paoletti, Giancarlo ^a   Belli, Franca ^a   Pizza, Carmine ^d   Giannarelli, Diana ^a   Lopez, Massimo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Oncologic Scientific Institute   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d Hospital S Maria della Pieta Casoria   (Italy)

Author keywords

Advanced breast cancer; Docetaxel; Epirubicin; Sequential chemotherapy; Vinorelbine

Indexed keywords

DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PREDNISONE; SEROTONIN ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; TAXOIDS; VINBLASTINE;

EID: 20244387298     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ahmann DL, Schaid DJ, Bisel HP et al.: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Oncol 15: 1928-1932, 1987.
2. Bastholt L, Dalmark M, Gjedde S et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patient with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14: 1146-1155, 1996.
3. Lopez M, Vici P, Di Lauro L et al: Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16: 86-92, 1998.
4. French Epirubicin Study: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6: 679-688, 1988.
5. Italian Multicenter Breast Study with Epirubicin: Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer. J Clin Oncol 6: 976-982, 1988.
6. Zoli W, Flamigni A, Frassineti GL et al: In vitro activity of Taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res 34: 63-69, 1995.
7. Fumoleau P: Treatment of patients with liver metastases. Anticancer Drugs 7: 21-33 (suppl 2): 1996.
8. Ravdin PM, Burris HA 3rd, Cook G et al: Phase II trial of docetacel in advanced anthracycline resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995.
9. Kouroussis C, Xydakis E, Potamianou A et al: Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. Ann Oncol 10: 547-552, 1999.
10. Mavroudis D, Alexopoulos A, Ziras N et al: Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study. Ann Oncol 11: 1249-1254, 2000.
11. Norton L: A gompertzian model of human breast cancer growth. Cancer Res 48: 7067-7071, 1988.
12. Norton L: Evolving concepts in systemic drug therapy of breast cancer. Semin Oncol 24: S10-3-S10-19, 1997.
13. Norton L and Simon R: Tumor size, sensitivity to tumor therapy, and design of treatment schedules. Cancer Treat Rep 61: 1307-1317, 1977.
14. Henderson IC, Berry DA, Demetri GD et al: Improved outcome from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983, 2003.
15. Riccardi A, Pugliese P, Danova M et al: A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer. Br J Cancer 85: 141-146, 2001.
16. Papadimitriou CA, Dimopoulos MA, Ampela C et al: Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer. Oncology 55: 533-537, 1998.
17. Schwartzberg L, Birch R, Weaver C et al: Randomized trial of simultanous (SIM) vs sequential (SEQ) doxorubicin (A) and docetaxel (T) in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 19: 72a (asbtr 278), 2000.
18. Paridaens R, Van Aelst F, Georgoulias V et al: A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Ann Oncol 14: 433-440, 2003.
19. Koroleva I, Wojtukiewicz M, Zaluski J et al: Preliminary results of a phase II randomized trial of Taxotere (T) and Doxorubicin (A) given combination or sequentially as first line chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20: 30a (abstr 117), 2001.
20. 2 (T100) and FEC75 as first line in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18: (abstr 456), 1999.
21. Delacroix V, Fumoleau P, Perrocheau G et al: Anthracycline as second-line chemotherapy (CT) for metastatic breast cancer patients previously treated with Taxotere (TXT). Proc Am Soc Clin Oncol 16: 166a, (abstr 578), 1997.
22. Vici P, Colucci G, Gebbia V et al: First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol 20: 2689-2694, 2002.
23. Simon R: Optimal two stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
24. Skipper HE: Analyses of multiarmed trials in which animals bearing different burdens of L1210 leukemia cells were treated with two, three, and four drug combinations delivered in different ways with varyng dose intensities of each drug and varying average dose intensities. Southern Research Institute Booklet 7: 42, 87, 1986.
25. Alba E, Ribelles N, Anton A et al: Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: A GEICAM-9801 phase II study. Breast Cancer Res Treat 77: 1-8, 2003.
26. Alba E, Martín M, Ramos M et al: Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish breast cancer group (GEICAM-9903) Phase III study. J Clin Oncol 22: 2587-2593, 2004.
27. Cresta S, Grasselli G, Mansutti M et al: A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 15: 433-439, 2004.
28. Khayat D, Chollet P, Antoine EC et al: Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 19: 3367-3375, 2001.
29. Perez EA, Geeraerts L, Suman VJ et al: A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patient with metastatic breast cancer. Ann Oncol 13: 1225-1235, 2002.
30. Fountzilas G, Papadimitirou C, Dafni U et al: Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol 19: 2232-2239, 2001.
31. Antón A, Hornedo J, Lluch A et al: A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 4: 286-291, 2003.
32. Gianni L: Paclitaxel plus doxorubicin in metastatic breast cancer: The Milan experience. Oncology 12: 13-18 (suppl 1), 1998.